Health Canada will not impose suffixes on non-proprietary names for biosimilars and brand biologics, the regulator has announced, in a move that has been welcomed by the Canadian Generic Pharmaceutical Association (CGPA).
“Following internal and external stakeholder consultations and analysis of related issues, Health Canada has decided that biologic drugs, including biosimilars, will be identified by their unique brand name and non-proprietary – common –